Urocit-K

Constipation, Uremia, Kidney Stones + 10 more

Treatment

7 FDA approvals

20 Active Studies for Urocit-K

What is Urocit-K

Potassium citrate

The Generic name of this drug

Treatment Summary

Potassium citrate, also known as tripotassium citrate, is a white, odorless powder with a salty taste. It is made up of 38.3% potassium. When mixed with water, it becomes highly hygroscopic and deliquescent. Potassium citrate is used to treat kidney stones and renal tubular acidosis. It is also used to manage a condition called hypocitraturic calcium oxalate nephrolithiasis.

Urocit-K

is the brand name

image of different drug pills on a surface

Urocit-K Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Urocit-K

Potassium citrate

1985

60

Approved as Treatment by the FDA

Potassium citrate, otherwise called Urocit-K, is approved by the FDA for 7 uses like uric acid and Nephrolithiasis .

uric acid

Nephrolithiasis

Tubular Acidosis; Renal

Helps manage Tubular Acidosis; Renal

uric acid lithiasis

Helps manage uric acid lithiasis

NEPHROLITHIASIS, CALCIUM OXALATE

Helps manage Hypocitraturic calcium oxalate nephrolithiasis

Renal tubular acidosis

Helps manage Tubular Acidosis; Renal

Lithiasis

Helps manage uric acid lithiasis

Effectiveness

How Urocit-K Affects Patients

Potassium citrate helps to prevent the formation of crystals and stones in the urine from salt compounds such as calcium oxalate, calcium phosphate and uric acid. It does this by increasing the citrate levels in the urine and binding with calcium, which decreases the activity of calcium ions and reduces the chances of calcium phosphate crystals forming. Additionally, it can stop the crystals from forming on their own.

How Urocit-K works in the body

Potassium citrate, taken orally, breaks down in the body to form an alkaline load. This then increases the amount of citrate in urine and raises the pH level, while also increasing the potassium level. In some cases, this can lead to a decrease in the amount of calcium in the urine.

When to interrupt dosage

The suggested amount of Urocit-K is contingent upon the diagnosed condition, including Metabolic Acidosis, laxative and Renal tubular acidosis. The dosage varies as per the mode of administration (e.g. Solution - Oral or Liquid) stated in the table beneath.

Condition

Dosage

Administration

Metabolic acidosis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Uremia

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Constipation

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Renal tubular acidosis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Bowel preparation therapy

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Kidney Stones

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Lithiasis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

NEPHROLITHIASIS, CALCIUM OXALATE

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Gout Flares

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Nephrolithiasis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Acidosis

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

uric acid

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

laxative

1100.0 mg/mL, , 550.0 mg/mL, 5.0 meq, 10.0 meq, 15.0 meq, 1080.0 mg, 3300.0 mg, 540.0 mg, 50.0 mg, 49.5 mg, 0.02 meq/mL, 19.5 mg/mL, 2.7 mg/mL, 2.17 mg/mL, 2.04 mg/mL, 282.0 mg, 847.0 mg, 20.0 mg/mL, 0.2 mg/mg, 6.25 mg, 5.0 mg, 5.4 mg, 40.0 mg, 0.5 mg/mL, 10.0 mg, 20.0 mg, 160.0 mg, 2.5 mg, 99.0 mg, 0.00148 mg/mg, 30.0 mg, 398.0 mg/mL, 975.0 mg, 1.193 mg/mg, 13.0 mg

Solution, Oral, Solution - Oral, , Tablet, Tablet - Oral, Tablet, extended release - Oral, Tablet, extended release, Granule, for solution - Oral, Granule, for solution, Liquid - Oral, Liquid, Syrup, Syrup - Oral, Powder, Powder - Oral, Capsule, Capsule - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Warnings

Urocit-K Contraindications

Condition

Risk Level

Notes

Hyperkalemia

Do Not Combine

Renal Insufficiency

Do Not Combine

Urinary tract infection

Do Not Combine

Gastrointestinal tract structure

Do Not Combine

Peptic Ulcer Disease

Do Not Combine

There are 20 known major drug interactions with Urocit-K.

Common Urocit-K Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

The excretion of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when combined with Potassium citrate.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The excretion of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when combined with Potassium citrate.

4-Bromo-2,5-dimethoxyamphetamine

Major

The excretion of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when combined with Potassium citrate.

Albutrepenonacog alfa

Major

The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Potassium citrate.

Amiloride

Major

The risk or severity of hyperkalemia can be increased when Potassium citrate is combined with Amiloride.

Urocit-K Toxicity & Overdose Risk

The toxic dose of the drug for dogs is 176mg/kg when administered intravenously.

image of a doctor in a lab doing drug, clinical research

Urocit-K Novel Uses: Which Conditions Have a Clinical Trial Featuring Urocit-K?

A total of 74 active clinical trials are assessing the potential of Urocit-K to provide Bowel preparation therapy, Kidney Stone Dissolution and Chronic Constipation Relief.

Condition

Clinical Trials

Trial Phases

Kidney Stones

32 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2

Constipation

18 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1

Bowel preparation therapy

1 Actively Recruiting

Phase 1, Phase 2

Metabolic acidosis

0 Actively Recruiting

NEPHROLITHIASIS, CALCIUM OXALATE

3 Actively Recruiting

Not Applicable

Gout Flares

1 Actively Recruiting

Phase 2

Nephrolithiasis

0 Actively Recruiting

Lithiasis

0 Actively Recruiting

uric acid

0 Actively Recruiting

Acidosis

0 Actively Recruiting

Uremia

0 Actively Recruiting

Renal tubular acidosis

0 Actively Recruiting

laxative

0 Actively Recruiting

Urocit-K Reviews: What are patients saying about Urocit-K?

4.7

Patient Review

3/11/2013

Urocit-K for Calcium Oxalate Kidney Stones

I took this for around eight months while I was deployed to Afghanistan. It was great because it's hard to diet there, and I had no side effects or stones. But then I got lazy and stopped taking it for a couple months, and that resulted in a small stone. So now I'm back on the medication again.

4

Patient Review

3/3/2009

Urocit-K for Kidney Stones caused by Cystine

I'm not usually one for taking medication, but this has been a lifesaver. I've been kidney stone free for almost two years now, and it's all thanks to this little pill. They're tough to swallow (literally), but I know it's worth it.

3.7

Patient Review

12/30/2008

Urocit-K for Calcium Oxalate Kidney Stones

The pills are large and not coated, making them hard to swallow. I've only just started taking the medication so I can't speak to its efficacy yet.

3

Patient Review

1/23/2010

Urocit-K for Calcium Oxalate Kidney Stones

I've only been on this medication for a week, but I have experienced significant heartburn relief. Additionally, this week I passed five kidney stones.

2.7

Patient Review

2/1/2009

Urocit-K for Prevention of Calcium-Containing Kidney Stones

I take it with meals to avoid the upset stomach that it sometimes causes. I use cold juice to help it go down. When I take it regularly, it seems to decrease the frequency of kidney stones (with the drug: one stone every ~10 yrs; without the drug: one stone every ~5 yrs).

2.7

Patient Review

1/9/2014

Urocit-K for Uric Acid Kidney Stones

I had some initial digestive issues with this medication, but those subsided after a few days. I continued to feel lousy for weeks afterwards though and stopped taking the drug as a result. However, since it could still be beneficial to me, I started taking it again. Unfortunately, my vision has changed since being on the medication (not a listed side effect) so now I need different glasses.

2.7

Patient Review

2/29/2012

Urocit-K for Calcium Oxalate Kidney Stones

My urologist believes that this medication will help me avoid future kidney stones, for which I've needed surgery in the past. The pills are large and very hard to swallow--they start dissolving as soon as you put them in your mouth! I have to take four per day, and it's easier to just down all my other pills at once than try to choke these things down one by one.

2.3

Patient Review

9/16/2015

Urocit-K for Calcium Oxalate Kidney Stones

I had to have six laser lithotripsy treatments to remove five stones that were too big to pass. It's only been two years and I've already made three more stones. I'm hoping this medication helps.

1.7

Patient Review

9/26/2007

Urocit-K for Uric Acid Kidney Stones

1.7

Patient Review

12/1/2008

Urocit-K for Prevention of Calcium-Containing Kidney Stones

I felt shaky and nauseous after taking this medication.

1.3

Patient Review

10/13/2013

Urocit-K for Uric Acid Kidney Stones

I am currently taking this medication for fibromyalgia. So far, I have not seen any improvement in my pain levels.

1

Patient Review

9/12/2009

Urocit-K for Uric Acid Kidney Stones

As long as you follow the instructions, this medication will help prevent kidney stones from forming.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about urocit-k

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Urocit-K the same as potassium citrate?

"Potassium citrate alters the pH of urine, making it less acidic. This allows the kidneys to excrete uric acid more efficiently, reducing the risk of kidney stones."

Answered by AI

What is Urocit-K used for?

"This medication is used in order to make the urine less acidic. The purpose of this is to help the kidneys get rid of uric acid, which also helps to prevent gout and kidney stones. This medication can also be used to prevent and treat certain metabolic problems (acidosis) that are caused by kidney disease."

Answered by AI

What are the side effects of Urocit-K?

"You may experience some side effects when taking potassium citrate, including nausea, vomiting, diarrhea, stomach pain or upset, or the appearance of a potassium citrate tablet in your stool."

Answered by AI

Is Urocit-K over the counter?

"Urocit-K is a prescription medication that helps to prevent kidney stones by restoring the chemical balance in the kidneys. It is available in three different dosage strengths, and reduces the formation of several common types of kidney stones, including calcium oxalate and uric acid stones."

Answered by AI

Clinical Trials for Urocit-K

Image of University of Michigan in Ann Arbor, United States.

Stent Omission vs Placement for Kidney Stones

18+
All Sexes
Ann Arbor, MI

The study is being completed to compare patient reported outcomes for stent omission vs. placement after using a ureteral access sheath for uncomplicated ureteroscopy. Participants that consent for the study will complete baseline PRO questionnaires. A UAS will be used during surgery, and the size left to the discretion of the surgeon. At the end of the procedure, the urologist will evaluate the ureter for iatrogenic injury, and the ureter will be graded using the Post Ureteroscopic Lesion Scale (PULS). Patients assessed with PULS 0 and PULS 1 will meet 2nd stage eligibility and will be randomized 1:1 to either stent omission or stent placement. When a stent is placed, the stent type and decision to leave a string (tether) will be at the operating urologist's discretion. Hypothesis: \- stent omission arm will be non-inferior to stent placement in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference and Pain Intensity, and have lower 30-day healthcare utilization.

Recruiting
Has No Placebo

University of Michigan

Khurshid Ghani, MD

Have you considered Urocit-K clinical trials?

We made a collection of clinical trials featuring Urocit-K, we think they might fit your search criteria.
Go to Trials
Image of United States, Alabama University of Alabama at Birmingham in Birmingham, United States.

Oxalate Synthesis for Kidney Stones

18 - 80
All Sexes
Birmingham, AL

The goal of this clinical trial study is to test if patients with idiopathic calcium oxalate kidney stones have an increased production of oxalate by the body, which would lead to increased urinary excretion of oxalate. The study will recruit adult patients with a history of calcium oxalate kidney stones and healthy volunteers without kidney stones. Participants will ingest fixed diets containing low amounts of oxalate for 5 days ingest a soluble form of glycolate and vitamin C collect urine, blood, stool during the dietary and oral dosing portions of the study and also collect breath sample during the oral glycolate test

Recruiting
Has No Placebo

United States, Alabama University of Alabama at Birmingham (+1 Sites)

Sonia Fargue, PhD

Have you considered Urocit-K clinical trials?

We made a collection of clinical trials featuring Urocit-K, we think they might fit your search criteria.
Go to Trials
Image of Hamilton Health Sciences in Hamilton, Canada.

Kiwifruit Extract for Constipation in Children

4 - 17
All Sexes
Hamilton, Canada

The goal of this pilot feasibility randomized controlled trial is to determine whether Actazin (kiwifruit extract) is a feasible and effective alternative to polyethylene glycol 3350 (PEG 3350) for maintenance therapy in children with functional constipation (FC). This study will include children aged 4 to 17 years who meet the Rome IV criteria for functional constipation. The main questions it aims to answer are: 1. Is it feasible to conduct a definitive, multi-centre trial comparing Actazin to PEG 3350 in children with FC? 2. What are the within-group differences in clinical outcomes such as stool frequency, abdominal pain, and laxative use over a 4-week period? Researchers will compare chewable Actazin tablets with placebo PEG 3350 powder to PEG 3350 powder with placebo Actazin tablets to see if Actazin is a viable non-pharmacologic natural health product alternative for treating FC. Participants will: Undergo an initial bowel cleanout using PEG 3350 and bisacodyl. Following, they will be randomized to one of two groups: 1. Actazin chewable tablets (titrate to effect: 600-2400 mg/day) + placebo PEG 3350 2. PEG 3350 (dose based on age and titratable to effect) + placebo Actazin chewable tablets Participants will take the assigned intervention daily for 4 weeks and complete a daily bowel diary recording stool frequency, consistency (Bristol Stool Scale), abdominal pain, and laxative use. They will have weekly follow-ups via phone or electronic survey to assess adherence, medication use, and adverse events. Additionally, a bi-weekly follow-up will be conducted for an additional 8 weeks to track longer-term outcomes. Outcomes: Primary feasibility outcomes include consent rate, adherence to allocated intervention, and 4-week follow-up completion rate. Secondary clinical outcomes include resolution of FC (Rome IV criteria), weekly stool frequency, abdominal pain episodes, use of rescue laxatives, and treatment palatability. This study is being conducted at McMaster Children's Hospital and is funded by the Hamilton Academic Health Sciences Organization (HAHSO). Data collection will be managed using the Lumedi™ platform, and safety will be overseen by a Data Safety Monitoring Board (DSMB).

Phase 2 & 3
Waitlist Available

Hamilton Health Sciences

Elyanne Ratcliffe, MD

Image of University of Alberta in Edmonton, Canada.

Pelvic Health Rehabilitation for Breast and Gynecologic Cancer

18+
Female
Edmonton, Canada

The GYVE study aims at testing an online program (eModule) to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues like urinary incontinence and pain during sex. These cancers and their treatments can cause significant pelvic health problems, affecting daily life and quality of life. Physiotherapy can help, but access is often limited due to costs and other barriers. The study will involve 20 participants from Quebec and Edmonton, who will take part in a 12-week program with weekly online group sessions led by a physiotherapist. Topics include pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Led by experts in cancer rehabilitation and pelvic health, the study aims to provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to broader implementation to help more people with lived experience of cancer.

Recruiting
Has No Placebo

University of Alberta (+1 Sites)

Have you considered Urocit-K clinical trials?

We made a collection of clinical trials featuring Urocit-K, we think they might fit your search criteria.
Go to Trials